Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Rubius Therapeutics Inc (RUBY)

Rubius Therapeutics Inc (RUBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Cellarity Announces Close of $121 Million Series C Financing Business Wire - Tue Oct 4, 2022

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 28.45 (-3.98%)
EVLO : 0.0005 (+66.67%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
RUBY : 0.0570 (+2.70%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior Business Wire - Wed Aug 17, 2022

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 28.45 (-3.98%)
EVLO : 0.0005 (+66.67%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
RUBY : 0.0570 (+2.70%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Tue Aug 9, 2022

New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial...

RUBY : 0.0570 (+2.70%)
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results Globe Newswire - Tue Jul 26, 2022

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.0570 (+2.70%)
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors PR Newswire - Tue Jul 19, 2022

/PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the...

RUBY : 0.0570 (+2.70%)
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting Globe Newswire - Wed Jun 22, 2022

Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens...

RUBY : 0.0570 (+2.70%)
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer Business Wire - Thu Jun 2, 2022

Flagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined...

DNLI : 28.45 (-3.98%)
EVLO : 0.0005 (+66.67%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
RUBY : 0.0570 (+2.70%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference Globe Newswire - Wed Jun 1, 2022

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.0570 (+2.70%)
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting Globe Newswire - Thu May 26, 2022

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.0570 (+2.70%)
Flagship Pioneering Unveils ProFound™ Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New Medicines Business Wire - Thu May 26, 2022

Flagship Pioneering, the bioplatform innovation company, today unveiled ProFound™ Therapeutics, a company that has identified a universe of previously undiscovered human proteins, enabling a multitude...

DNLI : 28.45 (-3.98%)
EVLO : 0.0005 (+66.67%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
RUBY : 0.0570 (+2.70%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)

Barchart Exclusives

2 Energy Dividend Stocks to Buy This November for Growth and Income Barchart - 1 hour ago
For investors seeking steady gains, these two dividend-paying energy stocks could be smart picks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot